The question most knee OA patients reach eventually

After months — sometimes years — of physiotherapy, painkillers, injections, and careful activity modification, many people with knee osteoarthritis arrive at the same quiet question: have I done enough to justify the next step? It is a reasonable question, and the honest answer is that there is no single moment when conservative care formally ends and surgery formally begins.

What clinicians look for instead is a pattern: treatments that once gave meaningful relief are now providing less of it, for shorter periods, despite a fair trial. That pattern has two converging signals — one functional, one structural. Functionally, pain is limiting the activities of everyday life in ways that are no longer acceptable to the patient: walking, sleeping, climbing stairs. Structurally, imaging confirms what is happening to the joint surfaces beneath those symptoms.

Neither signal is sufficient on its own. Significant cartilage loss on an MRI does not automatically mean surgery is due; nor does pain severity alone, without knowing the structural stage. The decision is individual, not formula-driven, and a specialist assessment — going beyond a GP questionnaire — is the appropriate moment to weigh both together.

What conservative care for knee OA actually covers

Conservative care for knee OA is not a single treatment — it is a sequence, and patients sometimes abandon one element after a single disappointing attempt without working through the full ladder.

First-line options form the foundation: supervised exercise and physiotherapy to strengthen the muscles supporting the knee, weight optimisation to reduce load across the joint, activity modification during flares, and simple analgesia — paracetamol or NSAIDs where medically appropriate. These are not temporary placeholders; they remain relevant throughout the pathway.

When first-line measures have been tried adequately and symptoms persist, intra-articular injections enter the picture as a recognised second-line step — not a separate pathway. Corticosteroid injections can settle acute inflammatory flares. Hyaluronic acid viscosupplementation aims to restore joint lubrication. Platelet-rich plasma (PRP) and polyacrylamide hydrogel (Arthrosamid®) are options for mild-to-moderate OA where cartilage is present but symptomatic. Their goal is to extend the conservative window and support function; they do not reverse the underlying disease, nor do they remove the need to maintain strength and manage load.

One important boundary applies here: injection therapies lose their effectiveness as OA advances towards bone-on-bone contact. Research consistently excludes end-stage disease from intra-articular hyaluronic acid trials precisely because outcomes drop markedly once cartilage loss is near-total. The more articular surface that remains, the more a bridging injection has to work with.

A complete conservative trial means working through both levels methodically — not discounting any modality after a single attempt before concluding the pathway has been exhausted.

Three zones: where you are in your OA journey

Most patients are unsure which zone they occupy — and that uncertainty is exactly why imaging review matters before any escalation decision is made. The three zones below are a navigation tool, not a rigid clinical classification; symptom intensity alone can misplace a patient in either direction.

Zone 1 — Mild OA. Some cartilage thinning is visible on imaging, but the joint space is broadly maintained. Pain occurs with activity rather than at rest. First-line measures — physiotherapy, load management, weight optimisation, and simple analgesia — remain the appropriate starting point and often provide meaningful relief.

Zone 2 — Mild-to-moderate OA, or early conservative failure. Cartilage is reduced across one or more compartments but is not fully absent. Symptoms continue to limit daily life despite adequate first-line care. This is the window for bridging therapies (PRP, hyaluronic acid, polyacrylamide hydrogel) or, in younger patients with varus alignment and unicompartmental disease, joint-preserving surgery such as high tibial osteotomy. The goal is to sustain function and defer more invasive steps where the joint structure still supports that approach.

Zone 3 — Advanced OA. The articular surface is largely gone, with bone-on-bone contact confirmed on imaging. Pain intrudes at rest and during the night; walking distance, stair-climbing, and sleep are all significantly affected. At this stage the joint has little remaining structure for non-surgical therapies to act on, and surgical planning — typically total knee replacement — becomes the appropriate next conversation.

Confirming the zone with imaging. Plain X-ray, measuring joint space width, is the standard first step. Where the picture remains unclear — when symptoms feel more severe than X-ray findings alone suggest — MRI adds cartilage detail, meniscal status, and subchondral bone signal. AI-assisted cartilage segmentation and T2 mapping, as used in onMRI™ assessment, can quantify cartilage loss more precisely than visual read alone, which is particularly useful in Zone 2 where the margin between conservative and surgical decisions is narrow.

Zone assignment is a clinical judgement anchored to imaging, not a verdict — and it can change as disease progresses.

Signals that conservative care is no longer working

Night pain is usually the clearest signal. When knee discomfort begins waking you from sleep, or is present while sitting or lying down rather than only during activity, something has shifted: the joint is no longer quiet at rest, and that pattern consistently marks the point at which clinicians begin reassessing the conservative pathway.

Beyond night pain, several other functional checkpoints are worth naming:

• Walking distance has shrunk noticeably — not because of a recent flare, but consistently, despite completing an adequate course of physiotherapy and load management.
• Stairs, low chairs, and getting in and out of a car have become reliably difficult or painful, even on ordinary days.
• Pain medication use is escalating or becoming routine without any corresponding improvement in what you can actually do; the tablets are managing the day rather than supporting recovery.
• The knee looks or feels different — persistent swelling, loss of full straightening or bending, or a visible change in alignment that was not there before.
• Validated scores are declining over time. A single WOMAC or KOOS assessment is a snapshot; a downward trend across two or three successive appointments is a more meaningful signal that the joint is not holding its own.

None of these checkpoints has to appear in isolation, and not all need to be present at once. Some patients carry considerable structural disease with relatively mild symptoms; others report severe functional impact that imaging underestimates. Individual variation is real, and this is precisely why the conversation with a knee specialist — supported by imaging — matters more than any single symptom threshold. These signals are prompts to have that conversation, not a prediction of what comes next.

Surgical options when the conservative window closes

The choice between surgical options turns on three factors: how much of the knee is affected, how alignment sits, and how active the patient intends to remain. These determine whether the right step is joint replacement or a procedure that preserves the original joint surface.

Total knee replacement (TKR) is the established answer for end-stage, multi-compartment disease — where bone-on-bone contact is confirmed across the knee and no meaningful cartilage architecture remains. TKR resurfaces the entire joint using metal and polyethylene components, eliminating the source of bone-on-bone pain and correcting alignment in one procedure. More than 700,000 are performed annually in the United States, and the long-term evidence base is extensive. It is the appropriate pathway for Zone 3 disease as described in the section above.

Unicompartmental knee replacement (UKR) applies where OA is genuinely confined to one compartment — most often the medial side — with an intact ACL and broadly preserved alignment elsewhere. Only the affected compartment is resurfaced, leaving the rest of the joint untouched. Patient selection is important: global or advanced multi-compartment disease generally favours TKR.

High tibial osteotomy (HTO) takes a different approach. Rather than replacing joint surfaces, it corrects varus (bow-legged) deformity by realigning the leg's weight-bearing axis, shifting load from the arthritic medial compartment to the healthier lateral side. This is typically suited to younger, more active patients with unicompartmental medial OA — and because no bone is removed from the joint surfaces, it preserves the option of knee replacement later if one is needed.

Joint-preserving options such as HTO and cartilage repair procedures belong in Zone 2; they are not suited to global bone-on-bone disease. The right surgical pathway is never determined by symptoms alone — age, activity demands, compartmental pattern, alignment, and patient preference all shape the decision. Where alignment and load distribution are clinically uncertain, objective biomechanical gait assessment — measuring how force tracks across knee compartments during walking, as captured by MAI Motion® — can add useful context to surgical planning alongside imaging findings.

Making the decision: what a specialist assessment involves

Recognising the signals in this guide is a starting point, not a verdict. A structured specialist review is how those signals are weighed against imaging, function, and individual goals to reach a decision that genuinely fits the patient.

A formal assessment typically covers four things: a detailed clinical history — what has been tried and for how long, and what the patient needs the knee to do; a functional examination of range of motion, alignment, and joint stability; outcome scoring (WOMAC or KOOS) to establish an objective baseline; and imaging review — weight-bearing X-rays as a minimum, with MRI where cartilage detail or zone classification is uncertain.

What distinguishes a useful decision conversation from a routine appointment is an explicit discussion of activity goals. What a 55-year-old hoping to return to recreational sport is weighing is materially different from what a 75-year-old who wants to walk comfortably without pain needs from the same joint. Shared decision-making — patient and clinician reviewing goals, imaging, and functional findings together — is the clinical standard. There is no fixed symptom-duration threshold before that conversation can begin.

Patients who recognise Zone 2 or early Zone 3 patterns in themselves — night pain, shrinking walking distance, or conservative treatments that are providing diminishing returns — do not need to wait for a GP referral to find out where they stand. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral, with consultant-led assessments at Sleaford NG34 and Grantham NG31. Book an assessment at lincolnshireknee.co.uk.

1. [1] Knee Cartilage Replacement Therapy – Wikipedia. https://en.wikipedia.org/?curid=4984243 https://en.wikipedia.org/?curid=4984243
2. [2] Osteoarthritis – Wikipedia. https://en.wikipedia.org/?curid=504841 https://en.wikipedia.org/?curid=504841
3. [3] Joint Replacement – Wikipedia. https://en.wikipedia.org/?curid=2867638 https://en.wikipedia.org/?curid=2867638
4. [4] Knee Replacement – Wikipedia. https://en.wikipedia.org/?curid=2830398 https://en.wikipedia.org/?curid=2830398